Prevention of delayed nausea: A university of rochester cancer center community clinical oncology program study of patients receiving chemotherapy

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3389-3395

  Roscoe, Joseph A ^a   Heckler, Charles E ^a   Morrow, Gary R ^a   Mohile, Supriya G ^a   Dakhil, Shaker R ^b   Wade, James L ^c   Kuebler, J Philip ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c Central Illinois CCOP   (United States)

^d Columbia Oncology Association ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; OXALIPLATIN; PALONOSETRON; PROCHLORPERAZINE;

ADD ON THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UROGENITAL TRACT CANCER;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; INTENTION TO TREAT ANALYSIS; ISOQUINOLINES; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; PROCHLORPERAZINE; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS;

EID: 84866755052     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8123     Document Type: Article

References (31)

1. Sun CC, Bodurka DC, Weaver CB, et al: Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227, 2005
2. Grunberg SM, Deuson RR, Mavros P, et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268, 2004
3. Molassiotis A, Saunders MP, Valle J, et al: A prospective observational study of chemotherapyrelated nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201-208, 2008
4. Pirri C, Katris P, Trotter J, et al: Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: A prospective, longitudinal, observational study. Support Care Cancer 19:1549-1563, 2011
5. Miller M, Kearney N: Chemotherapy-related nausea and vomiting: Past reflections, present practice and future management. Eur J Cancer Care 13:71-81, 2004
6. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
7. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21:v232-v243, 2010 (suppl 5)
8. Aapro MS, Grunberg SM, Manikhas GM, et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449, 2006
9. Herrstedt J: Antiemetics: An update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5:32-43, 2008
10. Rapoport BL, Jordan K, Boice JA, et al: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 18:423-431, 2010
11. Grunberg SM, Dugan M, Muss H, et al: Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17:589-594, 2009
12. Yeo W, Mo FK, Suen JJ, et al: A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113:529-535, 2009
13. Bloechl-Daum B, Deuson RR, Mavros P, et al: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478, 2006
14. Ballatori E, Roila F, Ruggeri B, et al: The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179-185, 2007
15. Hilarius DL, Kloeg PH, van der Wall E, et al: Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support Care Cancer 20:107-117, 2012
16. Roscoe JA, Morrow GR, Colagiuri B, et al: Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 18:869-876, 2010
17. Hickok JT, Roscoe JA, Morrow GR, et al: 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomised controlled trial. Lancet Oncol 6:765-772, 2005
18. Box GEP, Cox DR: An analysis of transformations. J R Stat Soc B 26:211-252, 1964
19. Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
20. Campos D, Pereira JR, Reinhardt RR, et al: Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767, 2001
21. Takahashi T, Hoshi E, Takagi M, et al: Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101:2455-2461, 2010
22. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
23. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
24. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving highdose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
25. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al: Comparison of an aprepitant regimen with a multipleday ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006, 2006
26. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 18:3409-3422, 2000
27. Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 18:233-240, 2007
28. Jordan K, Sippel C, Schmoll HJ: Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 12:1143-1150, 2007
29. Navari RM: Overview of the updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Community Oncol 4:3-11, 2007
30. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
31. Celio L, Frustaci S, Denaro A, et al: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225, 2011